|
Pune based, Serigen Mediproducts, a biomedical products manufacturing company has raised Rs. 10 crore from IAN Alpha Fund & Colossa Ventures, along with existing and new angel investors. This significant financial boost will be instrumental in furthering the company’s mission to revolutionize regenerative medicine.
The company is also a part of BioAngels' portfolio company, which aligns with their vision of advancing biotechnology innovations. Serigen is at the forefront of developing tissue regeneration products using silk proteins. With a focus on innovation, the company aims to revolutionize regenerative medicine through cutting-edge research and development.
It has developed three innovative products: Serioss, an osteoconductive bone void filler, Seriderm, an absorbent wound dressing designed using silk protein to accelerate wound healing, and Serimat, a silk protein mesh used in reconstruction surgeries of various organs, including breast reconstruction, abdominal wall reconstruction, and dural repair. These products offer cutting-edge solutions for medical professionals, leveraging the unique properties of silk protein to enhance patient outcomes in wound care and surgical procedures.
Anuya Nisal, founder & CEO, Serigen Mediproducts, said “We are delighted to welcome new institutional investors like the IAN Alpha Fund in this round of funding and thank them for their faith in the company. We are also grateful for existing/incoming angel investors and Colossa Ventures for their support of Serigen. The proceeds of the funding will be directed towards completion of clinical trials, obtaining Indian and global regulatory approvals for our product lines, accelerating sales and marketing efforts, and building and strengthening our team.”
Sarika Saxena, managing partner IAN Alpha Fund, said “Serigen reflects IAN Alpha Fund’s thesis to invest in innovation and solving real problems. We look forward to working with the founders, Dr Premnath Venugopalan, Dr Anuya Nisal and Dr Swati Shukla and their vision of building a globally acclaimed company.”
Ashu Suyash, founder and CEO, Colossa Ventures, said “Serigen’s innovative approach to leveraging silk proteins for critical care solutions aligns with our mission to back women-led ventures that are poised for scalable growth and can also drive meaningful impact. We look forward to seeing Serigen's products transform patient care and set new standards in the medical field.”
Serigen Mediproducts has garnered widespread recognition. The company was the winner of the Poster Pitch at the Business Innovation Competition of the Orthopaedic Research Society, USA in 2024 and has been a recipient of prestigious grants such as the DBT BIRAC BIG, SBIRI, and BIPP, to name a few.
|